John Libbey Eurotext

Innovations & Thérapeutiques en Oncologie

MENU

Present and future management with immunotherapy in metastatic non-small cell lung cancer Volume 4, issue 4, Juillet-Août 2018

Figures

  • Figure 1
  • Figure 2

Tables

Author
Centre Oscar Lambret
3, rue Frédéric Combemale
BP 307 - 59020 Lille Cedex
France
* Tirés à part
  • Key words: immunotherapy, metastatic non-small cell lung cancer, anti-PD-1, anti-PD-L1, immunotoxicity
  • DOI : 10.1684/ito.2018.0130
  • Page(s) : 189-96
  • Published in: 2018

The management of metastatic non-small cell lung cancers (NSCLCs) has changed significantly with the identification of oncogenic mutations (in EGFR, ALK, ROS1, BRAF, etc.), which are believed to show a cumulative effect. Specific inhibition of the effects of these mutations may result in significant benefits in terms of response, survival, and quality of life. The more recent emergence of immune checkpoint inhibitors also represents a major therapeutic advance. These treatments (anti-PD-1, anti-PD-L1, and anti-CTLA-4), grouped under the general term “immunotherapy”, disturb the therapeutic algorithms of metastatic NSCLC. Immunotherapy has become a second-line therapeutic standard and a first-line recommendation for tumours that strongly overexpress the PD-L1 ligand. Immunotherapy also opens up interesting prospects in terms of being combined with, or used in addition to, chemotherapy. This review describes the main clinical results of immunotherapy for metastatic NSCLC, its toxicity, and future development.